DTCFFDEFENCE THERAPEUTICS INC

About DEFENCE THERAPEUTICS INC (DTCFF)

DEFENCE THERAPEUTICS INC (DTCFF) is a Biotechnology company headquartered in Vancouver, BC, Canada whose shares trade over-the-counter on the OTCQB tier.

Defence Therapeutics Inc. is a biotechnology company engaged in the business of research and development, focusing on enhancing delivery of tumor and infectious disease-specific therapeutics using its proprietary Accum® platform. The principal business carried on is the development of a biological drug enhancer platform that improves the efficacy and safety of a multitude of biological/biosimilar-based pharmaceuticals used in the treatment of cancer and infectious diseases.

Products and services

Defence Therapeutics Inc. is a biotechnology company engaged in the business of research and development, focusing on enhancing delivery of tumor and infectious disease-specific therapeutics using its proprietary Accum® platform. The principal business carried on is the development of a biological drug enhancer platform that improves the efficacy and safety of a multitude of biological/biosimilar-based pharmaceuticals used in the treatment of cancer and infectious diseases.

DTCFF key facts

Ticker symbol

DTCFF

Market tier

OTCQB

Sector

Healthcare

Industry

Biotechnology

Headquarters

Vancouver, BC, Canada

Country of incorporation

CA

Year of incorporation

2020

Employees

2

Estimated market cap

$41.47M (as of May 9, 2025)

Shares outstanding

54,725,370

Reporting standard

International Reporting: Canadian Securities Exchange

Audit status

Audited

Fiscal year end

6/30

Latest filing

Interim Financial Report (Dec 31, 2024)

DEFENCE THERAPEUTICS INC leadership

• Sebastien Plouffe — CEO, President
• Arnab De — CFO
• Patrick Joseph Meagher — CFO
• Dr. Moutih Rafei — Chief Scientific Officer

Explore more: Biotechnology stocks · Healthcare sector · OTCQB stocks · OTC stocks starting with D